Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells

Abstract

Endogenous b-galactose-binding lectins have many biological functions, but their biological significance in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) remains unclear. By immunohistochemistry, we analyzed the expression of galectin-1 and galectin-3 in HL and ALCL cases as well as in cell lines, and investigated the pharmacological effects of galectin-1 treatment with and without CD30 pre-stimulation of HL and ALCL cell lines. The galectin-3-negative human embryonic kidney cell line (HEK-293) was transfected with galectin-3 cDNA. Galectin-3 is differentially expressed in HL and ALCL. CD30 stimulation of the ALCL cell line Karpas 299 activates NF-kB without induction of apoptosis. Galectin-1 treatment of Karpas 299 induces cell death, which is significantly increased by CD30 pre-stimulation. The CD30-mediated increase of galectin-1-induced cell death is to some extent caspase independent and does not influence the expression of tumor necrosis factor-associated factor 1 (TRAF1), TRAF2, and cellular inhibitor of apoptosis 2 protein (cIAP2), as revealed in Karpas 299 cells. In other cell lines except Karpas 299, CD30 pre-stimulation did not significantly enhance galectin-1-induced cell death. Galectin-3 transfection of HEK-293 cells resulted in cell surface expression of galectin-3, associated with marked cell aggregation. CD30-targeted therapy in combination with galectin-1 treatment may induce effective killing of ALCL cells but not of HL cells.

Molecular cloning, expression of a galectin gene in Pacific white shrimp Litopenaeus vannamei and the antibacterial activity of its recombinant protein

“…For example, the stimulation of the mitochondrial apoptotic pathway by galectin-1 initiated ceramide release and the requirement of prophenoloxidase system for ceramide-induced apoptosis prompted us to investigate the role of the p53 pathway for cell death (Bremer et al, 2006;Hahn et al, 2004). Previously research demonstrated that galectin-1 can induce cell death of T cells and thymocytes, while other groups have shown that galectin-1 can kill B cells, breast cancer cells and prostate cancer cells (Kurushima et al, 2005;Suzuki et al, 2012). Galectins introduces chemotaxis, activation, oxidative activity and degranulation of eosinophils (Bremer et al, 2006;Paz et al, 2001).…”

Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: Regulatory roles of cell surface glycans

“…Galectin-1 is expressed in anaplastic large cell lymphoma (ALCL) as well as Hodgkin lymphoma (HL) (1). However, the biological significance of galectin-1 still remains unclear.…”

Prognostic Biomarkers for Hodgkin Lymphoma

“…High levels of LGALS1 have been found in HL patients with advanced stages, and LGALS1 might represent a potential biomarker in HL [208][209][210][211][212][213][214][215]. The protein is expressed by Reed-Sternberg cells and is an important regulator of tumor-immune escape and immune cell homeostasis.…”